Filing Details
- Accession Number:
- 0001179110-20-001668
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-14 18:54:19
- Reporting Period:
- 2020-02-12
- Accepted Time:
- 2020-02-14 18:54:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1235010 | Momenta Pharmaceuticals Inc | MNTA | Biological Products, (No Disgnostic Substances) (2836) | 043561634 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1716468 | M. Anthony Manning | C/O Momenta Pharmaceuticals, Inc. 301 Binney Street Cambridge MA 02142 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-02-12 | 25,000 | $0.00 | 30,857 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-02-13 | 8,541 | $30.03 | 22,316 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-12 | 789 | $31.63 | 21,527 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Acquisiton | 2020-02-12 | 25,000 | $0.00 | 25,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | M | Direct |
Footnotes
- Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018.
- Restricted Stock Units convert into common stock on a one-for-one basis.
- This transaction was effected pursuant to a Rule 10b5-1 plan.
- This transaction was executed in multiple trades at prices ranging from $31.23 to $31.99 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date.
Billionaire Hedge Funds
